Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention

Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention

Background: East Asian patients receiving treatment with the potent P<sub>2</sub>Y<sub>12</sub> inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Methods: This study investigated differences in OPR rates with reduced doses of...

Full description

Bibliographic Details
Main Authors: Kai Song, Xuan Jin, Moo-Hyun Kim, Jia-Xin Li, Cai-De Jin, Song-Lin Yuan, Zhao-Yan Song, En-Ze Jin, Kwang-Min Lee, Kyung-Hee Lim, Young-Rak Cho
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Journal of Clinical Medicine
Subjects:
optimal platelet reactivity
P2Y12 inhibitors
VerifyNow
multiple electrode aggregometry
light transmittance aggregometry
Online Access:https://www.mdpi.com/2077-0383/11/9/2480

Internet

https://www.mdpi.com/2077-0383/11/9/2480

Similar Items